Andrew R Branagan

31PUBLICATIONS
78CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Jul 08, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

|Apr 22, 2026
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

|Apr 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

|Mar 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

Jorge J Castillo, Andrew R Branagan, Alberto Guijosa

|Feb 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Hao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu

|Feb 03, 2026
Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Alberto Guijosa, Nicholas Tsakmaklis, Margaret Kobs

Pageof 6

Frequent Collaborators

20 joint publications

Jorge J Castillo

20 joint publications

Steven P Treon

16 joint publications

Zachary R Hunter

11 joint publications

Andrew J Yee